Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | APLNR | P35414 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3027061 | 0.83 | APLNR (0.59) | TSHRAPLNR | |
| SCHEMBL16316320 | 0.82 | LTA4H (0.52) | LTA4HALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL22210564 | 0.81 | LTA4H (0.50) | LTA4HALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL21803815 | 0.80 | SLC1A5 (0.47) | TSHRLTA4HKDM4EMEN1KMT2A | |
| SCHEMBL13719038 | 0.79 | LTA4H (0.41) | TSHRLTA4HALDH1A1PPARGPPARD | |
| SCHEMBL6062347 | 0.79 | LTA4H (0.48) | LTA4HALDH1A1PPARGPPARDPPARA | |
| SCHEMBL25809767 | 0.78 | HRH1 (0.58) | — | |
| SCHEMBL5018921 | 0.76 | SLC6A4 (0.58) | PPARA | |
| SCHEMBL7449929 | 0.76 | GABRA1 (0.53) | LTA4HALDH1A1PPARGPPARDPPARA | |
| SCHEMBL7445377 | 0.76 | MAOB (0.44) | TSHRLTA4HALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579479-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7241780-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOLS-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, ACACA | TSHR 780/4885LTA4H 3219/4885ALDH1A1 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.